Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 7/20 | 0.44 |
| ▸ | MMEL1 | Q495T6 | 3/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13825641 | 0.95 | TRPV1 (0.51) | MMEMMEL1TRPV1ITGB3ITGA2B | |
| SCHEMBL13825652 | 0.95 | TRPV1 (0.51) | MMEMMEL1TRPV1ITGB3ITGA2B | |
| SCHEMBL13825640 | 0.88 | MME (0.50) | HDAC2HDAC8MMEMMEL1ITGB3 | |
| SCHEMBL13825639 | 0.86 | HTT (0.46) | ALDH1A1MMEMMEL1CNR1ESR1 | |
| SCHEMBL12009637 | 0.83 | HPGD (0.52) | ALDH1A1HDAC2HDAC8CNR1TRPV1 | |
| SCHEMBL13825638 | 0.82 | ALDH1A1 (0.50) | ALDH1A1MMEMMEL1 | |
| SCHEMBL10002224 | 0.81 | CNR1 (0.57) | ALDH1A1HDAC2HDAC8MMECNR1 | |
| SCHEMBL12009663 | 0.81 | TRPV1 (0.49) | TRPV1ITGB3ITGA2B | |
| SCHEMBL12009660 | 0.81 | TRPV1 (0.49) | TRPV1ITGB3ITGA2B | |
| SCHEMBL14532490 | 0.80 | ESR1 (0.50) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796254-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8309766-B2 | Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof | Obschestvo S. Organichennoi Otvetstvennostiyu Pharmenterprises (RU) | 2012-11-13 | — | — | US | disclosed |
| US-20090111874-A1 | Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU PHARMENTERPRISES (RU) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111874-A1 | Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof | PAH, MAOA, APEH | ALDH1A1 781/4885HDAC2 1589/4885HDAC8 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.